Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 7,628 matching trials from the live ClinicalTrials.gov search.

Filters: Jacksonville, Florida Clear all

Conditions: Diastolic Heart Failure
Interventions: alagebrium, placebo; Drug
Lead sponsor: Synvista Therapeutics, Inc; Industry
Eligibility: 50 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 30
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 27 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Ipilimumab, Nivolumab, Carboplatin, Paclitaxel, Pemetrexed, Cisplatin; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 719 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 16
States / cities: Colorado Springs, Colorado • Plainville, Connecticut • Jacksonville, Florida + 12 more

Conditions: ISS Stage III Plasma Cell Myeloma, Multiple Myeloma
Interventions: Bone Marrow Aspiration and Biopsy, Carfilzomib, Computed Tomography, Daratumumab, Dexamethasone, Lenalidomide, Magnetic Resonance Imaging, Positron Emission Tomography, Multigated Acquisition Scan, Biospecimen Collection, Echocardiography, Chest Radiography; Procedure · Drug · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Restless Legs Syndrome
Interventions: Pramipexole; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 52
States / cities: Birmingham, Alabama • Dothan, Alabama • Mesa, Arizona + 47 more

Conditions: Tumor Lysis Syndrome, Cancer, Hyperuricemia
Interventions: Rasburicase (SR29142), Allopurinol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 15
States / cities: Berkeley, California • Los Angeles, California • Denver, Colorado + 12 more

Conditions: Ovarian Neoplasms
Interventions: Sorafenib (Nexavar, BAY43-9006), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 4
States / cities: La Jolla, California • Jacksonville, Florida • Augusta, Georgia + 1 more

Conditions: COVID-19 Pneumonia
Interventions: Tociliuzumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 24
States / cities: Phoenix, Arizona • Fullerton, California • Los Angeles, California + 19 more

Conditions: SARS-CoV-2 Infection
Interventions: Moderna COVID-19 Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 29 Years
Enrollment: 1,923 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 51
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 45 more

Conditions: Wound Heal, Ulcer
Interventions: InnovaMatrix® AC; Device
Lead sponsor: ConvaTec Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 21
States / cities: Fresno, California • Los Angeles, California • San Diego, California + 16 more

Conditions: Endometriosis
Interventions: Tanezumab, Placebo; Biological · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 30
States / cities: Mobile, Alabama • Tucson, Arizona • San Diego, California + 20 more

Conditions: Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection, C. Diff, CDI, Recurrent C. Diff, rCDI, C. Difficile, Recurrent CDI, FMT, Fecal Microbiota, Fecal Transplant
Interventions: CP101; Biological
Lead sponsor: Finch Research and Development LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 53
States / cities: Scottsdale, Arizona • Los Angeles, California • Murrieta, California + 47 more

Conditions: Bladder, Neurogenic
Interventions: tamsulosin hydrochloride; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 2 Years to 16 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 16 more

Conditions: Autistic Disorder, Autism, Asperger's Disorder, Asperger Syndrome, Autism Spectrum Disorders, Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS)
Interventions: Memantine Hydrochloride (HCl), Placebo capsules; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 479 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 64
States / cities: Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more

Conditions: Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Interventions: NNC6019-0001, Placebo (NNC6019-0001); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 9
States / cities: Phoenix, Arizona • Beverly Hills, California • Stanford, California + 5 more

Conditions: Irritable Bowel Syndrome With Constipation, Functional Constipation
Interventions: Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers), Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 65
States / cities: Birmingham, Alabama • Foley, Alabama • Saraland, Alabama + 50 more

Conditions: Embryonal Rhabdomyosarcoma, Fusion-Negative Alveolar Rhabdomyosarcoma, Spindle Cell/Sclerosing Rhabdomyosarcoma
Interventions: Biopsy Procedure, Bone Scan, Computed Tomography, Cyclophosphamide, Dactinomycin, Magnetic Resonance Elastography, Positron Emission Tomography, Radiation Therapy, Vincristine; Procedure · Drug · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 166
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 129 more

Conditions: HIV Infections
Interventions: Somatropin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 4 Years to 13 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 18
States / cities: Phoenix, Arizona • Los Angeles, California • San Diego, California + 13 more

Conditions: Bronchopulmonary Dysplasia
Interventions: Sildenafil, Placebo; Drug · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 7 Days to 28 Days
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 14
States / cities: Little Rock, Arkansas • Jacksonville, Florida • Chicago, Illinois + 10 more

Conditions: Menopause
Interventions: Estradiol, Progesterone, Placebo; Drug
Lead sponsor: TherapeuticsMD; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 1,845 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 119
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 99 more

Conditions: Transthyretin-Mediated Amyloidosis, ATTR Amyloidosis
Interventions: Not listed
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2033
U.S. locations: 13
States / cities: La Jolla, California • Los Angeles, California • Jacksonville, Florida + 10 more

Conditions: Melanoma, Head and Neck Cancer, Non Small Cell Lung Cancer, Urothelial Carcinoma
Interventions: Enoblituzumab Schedule 1, Pembrolizumab, Enoblituzumab Schedule 2, retifanlimab; Biological
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 20
States / cities: Scottsdale, Arizona • Newark, Delaware • Jacksonville, Florida + 17 more

Conditions: Cardiac Arrhythmia
Interventions: PURE EP 2; Device
Lead sponsor: BioSig Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Jacksonville, Florida • Boston, Massachusetts • Austin, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: Sotagliflozin (SAR439954), Placebo, Metformin; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 67
States / cities: Birmingham, Alabama • Phoenix, Arizona • Canoga Park, California + 50 more

Conditions: HIV Infections
Interventions: Ritonavir, Nelfinavir mesylate, Nevirapine, Lamivudine, Stavudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 4 Months to 17 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 53
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 32 more

Search by objective public record fields.

Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I)

A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer

A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia

A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine

IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers

A Clinical Study To Investigate The Effectiveness And Safety Of Tanezumab In Treating Pain Associated With Endometriosis

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder

Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine

A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

Growth Hormone Treatment of Children With HIV-Associated Growth Failure

Safety of Sildenafil in Premature Infants

A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

Novel Cardiac Signal Processing System

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin

Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens